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Tackling immunosenescence to improve COVID-19 outcomes 
and vaccine response in older adults
The COVID-19 pandemic serves as a potent reminder that 
older people are at very high risk of adverse outcomes 
from infectious disease because of comorbidities 
associated with ageing and decreased immunological 
competence (immunosenescence). Care home resi-
dents are particularly at risk because physiological 
vulnerability is compounded by cohabitation with other 
frail adults, increasing exposure and risk of infection. 
Immunosenescence not only increases susceptibility to 
disease but also blunts the effectiveness of vaccines1—one 
of our most powerful tools for preventing infections—
with annual influenza vaccinations only 30–40% effective 
in the most at-risk older populations. In the race for 
creating a vaccine against COVID-19, immunosenescence 
is most likely to present a disincentive to the inclusion of 
older people in trials, and vaccine formulations effective 
in younger people (<65 years) might not engender 
immunity in older populations. Finding ways to alleviate 
immunosenescence is a priority to improve the health 
of ageing populations, but to do so requires a robust 
understanding of the underlying causes of age-related 
decline and immunosenescence.
Biological ageing results in loss of physiological 
reserve—the capacity of a cell, tissue, or organ system 
to function beyond its basal level in response to 
increases in physiological demands. This loss of reserve 
is now known to be underpinned by a discrete set 
of biological mechanisms that can be therapeutically 
targeted. One such mechanism is cellular senescence, 
leading to the accumulation of dysfunctional cells 
that secrete tissue-degrading proteases plus pro-
inflammatory cytokines and chemokines, causing local 
and systemic harm. Senescence of immune cells (eg, 
via proliferative exhaustion), combined with depletion 
of naive T cells through thymic atrophy, exacerbates 
age-related loss of immunity to novel pathogens and 
vaccines. Approaches aimed at restoring immune 
function and improving tissue and organ physiology 
are thus likely to be important in mitigating the 
catastrophic effect of infections on older people.
Geroprotectors are drugs that target core biological 
mechanisms underlying ageing2,3 and are able to 
counteract the loss of function occurring with age in 
multiple organ systems, including the immune system. 
Molecular target FDA-approved indication Effect on senescence or immunosenescence
mTOR inhibitors: 
first generation (allosteric, 
non-competitive)—sirolimus 
and everolimus; 
second generation (active 
site inhibitors, competitive 
with ATP)—RTB101 and 
AZD8055
First generation inhibitors 
target mTORC1, decrease 
translation, increase 
autophagy and alter 
metabolism; second 
generation inhibitors target 
mTORC1 and possibly 
mTORC2, as above and also 
affect cytoskeleton
Cancer; immunosuppressant 
in kidney transplant rejection 
and some autoimmune 
conditions (NB doses for 
these indications are far 
higher than those that 
provide geroprotection)
Improve outcomes in many age-related diseases;4 improve 
response to flu vaccination5 (ACTRN12613001351707); decrease 
incidence and severity of respiratory tract infections in older 
adults;6 sirolimus in trials (NCT04341675) for COVID-19 
pneumonia; RTB101 in trials for COVID-19 prophylaxis in older 
people in the community (NCT04584710) or in nursing homes 
(NCT04409327), geroprotective at 1/120th maximum tolerated 
dose, well tolerated in older adults
Statins Pleiotropic: main target is 
the HMG-CoA reductase 
pathway; might also target 
small G protein Rho, 
affecting the actin 
cytoskeleton and cell 
motility
Reduction of low density 
lipoprotein cholesterol
Increase neutrophil cytokinesis and NETosis; decrease sepsis, 
organ failure and death in older adults hospitalised with 
community acquired pneumonia7 (EudraCT 2012-00343-29); 
currently in many trials for COVID-19 (NCT04407273, 
NCT04390074, NCT04348695, NCT04426084, NCT04333407, 
NCT04380402, and NCT04343001) and reported to COVID-19 
deaths8
Dasatinib (in combination 
with plant flavonoid 
quercetin)
src-family tyrosine kinase 
inhibitor (also inhibits 
BCR-ABL kinase)
Cancer Senolytic—ie, selectively kill senescent cells; improve 
physiological function in idiopathic pulmonary fibrosis;9 
in phase 2 trials in chronic kidney disease (NCT02848131)
Metformin Pleiotropic: main target is 
mitochondrial complex I, 
inhibition of which leads to 
activation of AMPK, 
and inhibition of acetyl CoA 
carboxylase; increases GLP-1 
in gut
Type 2 diabetes Immunomodulatory especially through T helper cell balance, 
leading to reduced autoantibodies, cytokines, and neutrophil 
NETosis; retrospective analysis suggests might improve 
outcomes for female patients with obesity and diabetes who 
have COVID-1910
Table: Examples of geroprotective agents
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These drugs might offer unique opportunities to protect 
vulnerable older people from infectious pathogens 
and might help to mitigate the consequences of acute 
infections and chronic multimorbidity, for example 
by acting to alleviate detrimental effects of senescent 
cells. Several drugs have shown geroprotective efficacy 
in preclinical testing, with several agents repurposed 
(often at very low doses) from existing alternative 
clinical indications (table). Of particular note for reversal 
of immunosenescence is that short-term treatment 
with geroprotective mTOR inhibitors (everolimus and 
BEZ235–RTB101 [Basel, Switzerland]) was found to 
improve responses to influenza vaccination in older 
adults, with benefits possibly persisting for a year after 
treatment.5 Such drugs suppress excess senescence-
associated inflammation while also improving innate 
immunity. RTB101 has been shown to upregulate 
interferon-induced antiviral gene expression in older 
adults,6 which is the first line of immune defence 
against viral infections such as COVID-19. Trials of 
RTB101 and other mTOR inhibitors to prevent and treat 
COVID-19 are ongoing (table). Similarly, statins can 
act as geroprotectors to support immunity, positively 
affecting innate and adaptive immune responses to 
improve pneumonia outcomes in older adults.7 Statins 
are also now being tested for benefit in COVID-19 
(table).8
Given such promise, what needs to happen now 
to make progress towards widespread clinical use of 
geroprotectors? The majority of current experimental 
drug trials—both for COVID-19 and for non-COVID 
infections—do not include older adults with multi-
morbidity. This exclusion of older people from trials 
must change if we are to understand the efficacy 
of new drugs in this population group who are at 
the highest risk. Additionally, randomised controlled 
trials of geroprotectors are needed, both as adjuvant 
therapy to enhance vaccine responses and to improve 
immunity in older people at risk of contracting 
COVID-19 and other infections. Care home residents, 
too often neglected during the COVID-19 pandemic, 
have much to gain from such an approach and should 
be prioritised for involvement in geroprotective trials. 
Candidate medications are already widely used in the 
clinic and have good safety profiles, especially at the 
low doses needed for geroprotection. Notably, short-
term treatment can give long-term protection, as seen 
with drugs that remove senescent cells (senolytics)9 that 
have a hit-and-run activity requiring only infrequent 
administration thus maximising benefit while min-
imising side-effects. Finally, we need regulatory bodies 
to support applications for appropriate clinical testing of 
geroprotectors, and to provide appropriate frameworks 
for their marketing authorisation and regulatory 
approval. The promise of geroprotective drugs will, 
if realised, extend far beyond the COVID-19 pandemic 
to improve overall health resilience in our ageing 
populations. Now is the time to test them.
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